Drugs / IMM27M
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06764836 | Jul 2024 → Jan 2026 overdue | hepatocellular carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05235438 | Jun 2022 → Aug 2023 | autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07687914 | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM27M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07687914 ↗ |
| Action | Inhibit | “Anti-CTLA-4 Humanized monoclonal antibody” NCT07687914 ↗ |
| Modality | Monoclonal antibody | “IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody)” NCT06764836 ↗ |
| Route | Intravenous | “Intravenous injection” NCT06764836 ↗ |